Hims & Hers Health, Inc. (NYSE:HIMS) Shares Sold by AQR Capital Management LLC

AQR Capital Management LLC trimmed its holdings in Hims & Hers Health, Inc. (NYSE:HIMS) by 43.5% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 47,887 shares of the company’s stock after selling 36,899 shares during the period. AQR Capital Management LLC’s holdings in Hims & Hers Health were worth $967,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also recently added to or reduced their stakes in the business. Nisa Investment Advisors LLC increased its position in Hims & Hers Health by 679.2% during the second quarter. Nisa Investment Advisors LLC now owns 1,839 shares of the company’s stock worth $37,000 after buying an additional 1,603 shares in the last quarter. Quest Partners LLC boosted its stake in shares of Hims & Hers Health by 5,944.1% during the second quarter. Quest Partners LLC now owns 3,566 shares of the company’s stock valued at $72,000 after acquiring an additional 3,507 shares during the last quarter. Van ECK Associates Corp purchased a new stake in Hims & Hers Health during the 2nd quarter worth about $111,000. Amalgamated Bank raised its stake in Hims & Hers Health by 55.9% in the 2nd quarter. Amalgamated Bank now owns 6,566 shares of the company’s stock valued at $133,000 after purchasing an additional 2,354 shares during the last quarter. Finally, Daiwa Securities Group Inc. purchased a new position in Hims & Hers Health in the 2nd quarter valued at about $142,000. 63.52% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Hims & Hers Health

In other news, insider Michael Chi sold 2,054 shares of the stock in a transaction dated Thursday, August 1st. The stock was sold at an average price of $22.00, for a total value of $45,188.00. Following the completion of the sale, the insider now owns 185,326 shares in the company, valued at approximately $4,077,172. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In other news, insider Michael Chi sold 2,054 shares of the business’s stock in a transaction on Thursday, August 1st. The shares were sold at an average price of $22.00, for a total transaction of $45,188.00. Following the transaction, the insider now directly owns 185,326 shares of the company’s stock, valued at approximately $4,077,172. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Andrew Dudum sold 188,888 shares of the company’s stock in a transaction on Tuesday, September 3rd. The shares were sold at an average price of $14.56, for a total transaction of $2,750,209.28. Following the completion of the transaction, the chief executive officer now owns 33,502 shares of the company’s stock, valued at $487,789.12. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 564,305 shares of company stock valued at $9,124,922 over the last three months. 17.71% of the stock is owned by company insiders.

Analyst Ratings Changes

A number of brokerages have recently commented on HIMS. TD Cowen lifted their price target on shares of Hims & Hers Health from $15.00 to $25.00 and gave the stock a “buy” rating in a report on Thursday, July 11th. Truist Financial lifted their target price on shares of Hims & Hers Health from $13.00 to $23.00 and gave the stock a “hold” rating in a research note on Thursday, July 18th. Imperial Capital lowered Hims & Hers Health from an “outperform” rating to an “in-line” rating in a research note on Friday, August 9th. Bank of America lowered their price objective on Hims & Hers Health from $24.00 to $20.00 and set a “buy” rating for the company in a research report on Friday, September 13th. Finally, Needham & Company LLC started coverage on Hims & Hers Health in a research report on Thursday, August 22nd. They set a “buy” rating and a $24.00 target price on the stock. Eight equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $19.86.

Hims & Hers Health Stock Performance

HIMS opened at $18.69 on Friday. The company has a market cap of $4.01 billion, a PE ratio of 233.65 and a beta of 1.06. Hims & Hers Health, Inc. has a 1 year low of $5.65 and a 1 year high of $25.74. The firm has a 50 day moving average price of $16.41 and a 200 day moving average price of $17.37.

Hims & Hers Health (NYSE:HIMS) last issued its earnings results on Monday, August 5th. The company reported $0.06 EPS for the quarter, beating analysts’ consensus estimates of $0.04 by $0.02. The business had revenue of $315.65 million for the quarter, compared to the consensus estimate of $302.43 million. Hims & Hers Health had a net margin of 1.70% and a return on equity of 5.25%. The business’s revenue for the quarter was up 51.8% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.03) EPS. On average, sell-side analysts predict that Hims & Hers Health, Inc. will post 0.22 earnings per share for the current year.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.